Original Publication Date: 1 December, 2014
Publication / Source: International Journal of Hematologic Oncology
Authors: Orietta Spinelli, Manuela Tosi, Marie Lorena Guinea Montalvo et al.
While adult acute lymphoblastic leukemia (ALL) is curable in 40–50% of the patients, the individual prognosis is rather unpredictable due to associated biological and clinical risk factors. In both B- and T-precursor ALL, minimal residual disease (MRD) represents the most sensitive prognostic marker, useful to support critical treatment decisions, ranging from allogeneic stem cell transplantation in patients with inadequate MRD response to chemotherapy only in MRD responsive ones.